Vendor Sponsored Studies
The Scientific Affairs group establishes and maintains continued financial support from our vendor partners and government contracts to conduct research studies and clinical trials focused on current and emerging transfusion-transmitted infectious disease agents. Our group has access to normal (infectious disease marker-negative) and marker-reactive blood samples representing a broad and geographically diverse population of the US, which can be utilized for potential new studies. Data supporting the characterization of our materials are available upon request. Data derived from these studies are used to support blood screening assay and pathogen reduction technology development, to affect policy decision making with respect to donor and recipient safety, and to recommend appropriate interventions as needed.
The Transfusion Innovation Department supports strategic research in line with the American Red Cross Mission. In addition to internal research and support, the Transfusion Innovation Teams at the Holland Laboratories and the Norfolk Clinical Research Laboratory collaborate with multiple commercial organizations in the product development lifecycle of new and modified medical devices, technologies and processes for the collection, manufacture, storage, and testing of blood products according to industry standards and in support of FDA licensure.
This includes contract research for FDA licensing studies (including radiolabeling in vivo procedures) for new blood products, new storage containers, platelet and red cell additive solutions, leukoreduction, irradiation, frozen blood, lyophilized blood, cell processing and washing, anaerobic storage and pathogen inactivation.
Senior Director, Operational Research
Project Manager II
Research Scientist-Manager - Co-Principal Investigator for Research
Senior Director, Transfusion Innovation, Principal Investigator
- Cancelas JA, West F, Karaffin M, Yoshida T, Rugg N, Whitley P, Dioguardi M, Brooks S, Wellington M, Iselin W, Dunham A. Long-Term Hypoxic/Hypocapnic Storage of Red Blood Cells Results in Amelioration of Lesion Hallmarks and Increased In Vivo Recovery at 24 Hours Post-Transfusion. Blood 2019;134 (Supplement a): 4995.
- Yoshida T, Whitley PH, Rugg N, Dioguardi M, Wellington M, Brooks S, Iselin W, Karafin MS, Cancelas Perez JA. Oxygen Saturation of Collected RBC Products is Donor Dependent. Transfusion 2019;59(S3).
- West FB, Whitley P, Haley S, Sawyer S, Wellington M, Evens H, Varfaj F, Erickson A. In Vitro Function evaluation of Amicus Amotosalen/UVA treated Platelets in 100% Plasma. Transfusion 2018;58(S2)
- Kausch K, Greay AD, Landrigan M, Whitley P, Wellington M, Sawyer S, Hanley S, Rugg N, Brunker PAR, Nestheide S, Mohmound F, Cancelas-Perez J. Rejuvenation Enhances Oxygen Release Capacity of 42 Day Stored Red Blood Cells Above Fresh Levels. Transfusion 2017;57(S3).
- Roback J, Zimring JC, Dumont LJ, Josephson C, Saakadze N, Barclay S, Waller EK, Jones DP, Maes LY, Wellington M, Whitley PH, Upple K. Identification of Metabolomic Signature that Correlate with Post-Transfusion Survival of Human RBCs. Transfusion 2016;56(S4).
- Cunnion K, Hair P, Krishna NK, Whitley PH, Goldberg C, Fadeyi EA, Maes LY. Discriminating Complement-Mediated Acute Transfusion Reaction (ATR) from Type O+ Erythrocytes Transfused into a B+ Recipient. 2016;56(7):1845-8.
- Dumont LJ, Cancelas JA, Maes LA, Whitley P, Herschel L, Siegel AH, Szczepiorkowski ZM, Hess JR, Zia M. Overnight, room temperature hold of whole blood followed by 42-day storage of red blood cells in additive solution-7. Transfusion 2015;55(3):485-90.